Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis

Inclusion Criteria: 1. Age ≥ 18 years old, gender is not limited; 2. Patients with medically prescribed rapamycin drug-eluting vertebral artery stent systems; 3. Patients and family members fully understand the trial's purpose, voluntarily participate in the trial and sign the informed consent form. Exclusion Criteria: 1. Unable to receive dual antiplatelet therapy due to known disease, or severe coagulation abnormalities, severe infections that are not controlled, severe systemic disease, uncontrollable hypertension, and contraindicated for surgery; 2. With an aneurysm that cannot be treated earlier or simultaneously or is not suitable for surgery; 3. Gastrointestinal disease with active bleeding; 4. Previous myocardial infarction or large-scale cerebral infarction within 2 weeks; 5. Known contraindications to heparin, rapamycin, anesthesia, and contrast agents; 6. Life expectancy less than 12 months; 7. the investigator judged patients to be unsuitable for participation in this study.